The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.
Olombel G, et al. Among authors: de labarthe a.
Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29.
Blood. 2016.
PMID: 26929274
Free article.
Clinical Trial.
No abstract available.